
EscharEx®

Next-Generation Enzymatic Debridement for Chronic Wounds



New SOC[1] Candidate


Modalities by Efficacy and Complexity




[1] standard of care

Superior Outcomes[2]

Debridement



Wound Bed Preparation



[2] Dove et al. 2025; *Wound*

Rapid Debridement and Facilitation of Wound Closure

Venous Leg Ulcers (VLU)		Diabetic Foot Ulcers (DFU)		Pressure Ulcers (PU)	
Before	After	Before	After	Before	After



- Investigational drug containing a sterile mixture of proteolytic enzymes
- Debrides chronic wounds within 4-8 applications
- Easy to use topical application in all patient settings
- Reduces bacteria and biofilm
- Promotes granulation tissue
- Demonstrated superiority over SANTYL®
- Aligns with treatment workflows & reimbursement landscape
- De-risked program; based on 3 successful Phase II trials
  - Ongoing Phase III trial for VLU
  - DFU trial planned H2 2026
  - PU Investigator-Initiated Trial (IIT) planned H2 2026
- Strategic research collaborations with Mölnlycke, Solventum, Medline, Essity, B. Braun, Coloplast, Convatec and MIMEDX